Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide

Trial Profile

Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arsenic trioxide (Primary) ; Corticosteroids
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms GvHD-ATO
  • Sponsors Medsenic
  • Most Recent Events

    • 12 Mar 2024 According to BioSenic Media Release, company announces the publication of an open-access article describing an optimized schedule for administration of oral arsenic trioxide (OATO) treatment for chronic graft-versus-host disease (cGvHD), based on an earlier post-hoc analysis of Phase 2 data. The schedule will play an important role in the protocol for BioSenic's forthcoming pivotal Phase 3 clinical trial.
    • 27 Sep 2023 According to BioSenic Media Release, company erforms further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD. This analysis will be used to decide on the best oral ATO's posology for BioSenic's forthcoming phase 3 clinical trial.
    • 27 Sep 2023 Post-hoc analysis results presented in a BioSenic Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top